Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759041 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Phase 2 study, sponsored by Seres Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT03759041 is a Phase 2 study that was terminated before completion, run by Seres Therapeutics. The registered enrollment target is 203 participants.
The verdict
NCT03759041, a Phase 2 study, was terminated before completion, sponsored by Seres Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
Interventions
- DRUG SER-287
- DRUG Vancomycin Pre-Treatment
- DRUG Placebo for Vancomycin Pre-Treatment
- DRUG Placebo for SER-287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03759041
The ClinicalTrials.gov registry entry for NCT03759041 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seres Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which SER-287 is the first listed.
NCT03759041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03759041 about?
NCT03759041 is a clinical study titled "A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis". A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
What is the current status of trial NCT03759041?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2018-12-19. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT03759041?
The interventions under investigation include: SER-287 (DRUG), Vancomycin Pre-Treatment (DRUG), Placebo for Vancomycin Pre-Treatment (DRUG), Placebo for SER-287 (DRUG).
Who is sponsoring clinical trial NCT03759041?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.